Abstracts A9 formulation resulted in less erosion from the total brand. In cases where branded utilization is not converted to TR formulation prior to launch of generic competition, such as risperidone and fluoxetine, or TR launch precedes generic launch by less than six months or not at all, such as azythromycin and sertraline, dramatic reduction in total sales brand was observed. In the unique case where branded escitalopram was introduced prior to the generic launch of citalopram, an effect similar to a branded TR launch was observed. CONCLUSIONS: While generic use typically replaces the majority of branded equivalents in a short timeframe, branded products with a timerelease formulation may limit uptake rate of the generic version of the total branded product. OBJECTIVES: Historic data suggest that most 1918 influenza pandemic-related deaths were due to pneumococcal disease (PD); preliminary evidence shows a similar pattern for the 2009 H1N1 influenza outbreak. Implementation of 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs would likely lessen the impact of a pandemic in Asia-Pacific populations that currently have low pneumococcal vaccination rates; our objective was to quantify this impact in Singapore and Hong Kong. METHODS: We used a decision-analytic model to assess the impact of PCV13 infant vaccination on PD incidence and mortality in an influenza pandemic in Singapore and Hong Kong versus no vaccination. The model was estimated from published sources; both direct and indirect (herd) effects against PD were included. Effectiveness of PCV13 was extrapolated from observed US 7-valent PCV (PCV7) data, using assumptions on serotype prevalence in the pre-PCV7 era, and PCV13 protection against the 6 serotypes not in PCV7. Country-specific data were used where available; where unavailable, US data were used. To simulate acceleration of PD transmission in a flu pandemic, we calibrated to 1918 estimates of countryspecific incidence and mortality, adjusting mortality for the advent of antibiotics. PD incidence and mortality, and total PD-related health-care costs were evaluated over a 1-year horizon. Results are reported in local 2008 currency. RESULTS: Preliminary results of the model indicate that in a pandemic of 1918 severity, PCV13 vaccination would prevent 3,300 cases of hospitalized pneumococcal pneumonia and 320 deaths in Singapore, and save SGD1.53 million in health-care costs (net of vaccination). In Hong Kong, PCV13 would prevent 8,200 cases of hospitalized pneumonia (all-cause), and 2,200 pneumonia deaths, respectively; PCV13 would save HKD250 million in medical costs. CONCLUSIONS: In an influenza pandemic affecting the Asia-Pacific region, infant vaccination with PCV13 would likely be highly effective in reducing pandemic-related deaths, PD cases and associated costs.
PODIUM SESSION III: HEALTH CARE DECISION-MAKER'S CASE STUDIES CASE1 IMPLEMENTATION OF A NONFORMULARY PRESCRIBING MONITORING SYSTEMS REVEALS OPPORTUNITIES FOR COST SAVINGS IN AN ACADEMIC MEDICAL CENTER
Helmons PJ, Daniels CE University of California San Diego Medical Center, San Diego, CA, USA ORGANIZATION: University of California San Diego Medical Center (UCSDMC) is a 548 bed academic medical center with an average daily census of 368 patients and 23,000 annual discharges. UCSDMC has a large regional footprint as it is the only academic medical center in the region and serves as the regions burn center and high risk obstetrics and neonatal care center. In addition, UCSDMC was the regions first level 1 trauma unit. Consequently, patients are admitted to UCSDMC with a wide variety of medications and insurance coverage. From a medication safety standpoint, outpatient maintenance medication is generally not substituted in our hospital. In addition, patients are discouraged to bring their own medication into the hospital to assure the quality of the medications. These patient population and policy characteristics make formulary management particularly challenging, as this practice results in a constant baseline use of nonformulary outpatient maintenance medications in our inpatient patient population. PROBLEM OR ISSUE ADDRESSED: Detecting trends in nonformulary prescribing is important as increased use of nonformulary medications could indicate an important clinical need of this medication. On the other hand, increased use of nonformulary medications in therapeutic areas with equivalent but less expensive formulary medications, leads to increased costs. We hypothesized that analyzing trends in nonformulary prescribing leads to detection of irrational and more expensive, nonformulary medications and therefore to cost savings. GOALS: To address these issues, we developed a nonformulary medication use monitoring system designed to improve formulary adherence by 50% and detect irrational nonformulary use at an early stage. OUTCOMES ITEMS USED IN THE DECISION: Formulary adherence is defined as the number of nonformulary medication doses billed divided by the total number of doses billed. As an example of irrational prescribing detected by this system, cost savings associated with reversing nonformulary levalbuterol use to formulary albuterol are reported. IMPLEMENTATION STRATEGY: Trends in nonformulary use are monitored using daily, monthly and semi-annual reports.-Daily monitoring is done by the clinical pharmacist. A report that specifies the nonformulary orders per nursing unit is sent to each pharmacist for follow up. The pharmacist evaluates the order for appropriateness and contacts the physician if substitution to a formulary alternative is possible. The intervention is recorded in the pharmacy information system and compliance is monitored by the pharmacoeconomics specialist.-Monthly monitoring is done by the pharmacoeconomics specialist. The results of this monthly analysis are discussed with the Pharmacist-in-Chief and with the Chair of the P&T Committee.-Semi-annual reporting is done by the pharmacoeconomics specialist. Trends in nonformulary prescribing over a six month period are discussed at the P&T meeting. An action plan is approved to address the findings. RESULTS: The first semi-annual nonformulary prescribing report showed a nonformulary use of 0.26% of billed doses. The most frequently prescribed nonformulary medications were: levalbuterol (bronchodilating agent), latanoprost (ocular glaucoma agent), pentosan (bladder relief agent) and Mg-Al plus (magnesium supplement). Based on this initial report and the lack of formulary alternatives, the P&T committee added the latter three agents to the formulary. However, from a cost savings standpoint, the use of levalbuterol at our institution was discouraged as this agent has no known benefits over our formulary agent albuterol. At the time of the report, levalbuterol was almost 4 times more expensive than albuterol. Collaboration with respiratory therapy and pulmonology was sought to educate prescribers and pharmacists about the therapeutic equivalence of albuterol and levalbuterol. After these interventions, the second semi-annual report showed an 80% decrease of nonformulary use to 0.05% of billed doses. Levalbuterol use decreased by 67% from an average of 24 patients per month in the 6 month period before the intervention to 8 patients after the intervention. Levalbuterol expenditure decreased from $7800 to $1421 over the same period and continues to drop, corresponding to an annualized cost avoidance of $8000. LESSONS LEARNED: This case study shows that in an environment where formulary management is challenging, a nonformulary prescribing monitoring system is successful in decreasing nonformulary prescribing and identifying areas of improvement. The large decrease in use of levalbuterol is only one of the successes resulting from this effort. However, by implementing continuous monitoring of nonformulary prescribing we expect to detect and prevent these excesses in the future. We acknowledge that the monetary savings of decreasing levalbuterol use and nonformulary prescribing as a whole is marginal. However, other benefits of a formulary that is better tailored to the institution's needs could include better inventory management, improved medication safety and less interruptions of therapy. This will be the focus of a subsequent study.
CASE2 INVENTING A TIERED FORMULARY BASED ON THE INCREMENTAL COST-EFFECTIVENESS OF DRUGS
Watkins J 1 , Sullivan S 2 , Ramsey S 3 , Wong E 1 , Veenstra D 2 , Burke W 4 , Roy Choudhury S 1 1 Premera Blue Cross, Mountlake Terrace, WA, USA, 2 University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 3 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 4 University of Washington, Department of Bioethics and Humanities, Seattle, WA, USA ORGANIZATION: Premera Blue Cross PROBLEM OR ISSUE ADDRESSED: Traditional U.S. payer drug selection processes are based on safety, efficacy and drug cost. As premiums continue to rise, many plan sponsors have responded by raising member cost shares on biologics and other high cost pharmaceuticals. This creates affordability barriers for these drugs, regardless of their clinical value, comparative effectiveness or cost-effectiveness. GOALS: Our novel cost-effectiveness driven formulary design seeks to offset the negative impact of such policies on clinical outcomes and quality of care by assigning the drugs that are the most incrementally cost-effective to the lowest formulary tiers. OUTCOMES ITEMS USED IN THE DECISION: Comparative effectiveness and safety (clinical benefits and harms as determined by our existing formulary process) and incremental cost-effectiveness ratios of specific therapies vs. usual care alternatives, based on published cost-effectiveness analyses, manufacturer-submitted cost-effectiveness models and in some cases, models developed internally by plan staff. Cost-effectiveness studies are subjected to a quality review process before being presented to the formulary committee. IMPLEMENTATION STRATEGY: Premera Blue Cross has created a formulary process that assigns each drug to one of four tiers based on a set of flexible cost-effectiveness thresholds. Incremental costeffectiveness, assessed as rigorously as possible, provides a scientific, transparent and defensible means of maintaining lower cost shares for the highest value drugs, regardless of actual prescription cost. In some cases, a drug may fall in more than one tier, based on the patient population and the particular indication for which it is being used. This presentation describes Premera's formulary process, how the thresholds for each tier were established and how drugs and therapeutic classes are reviewed by an external multidisciplinary expert committee, with specific therapeutic drug class outcome examples. This formulary is being offered as part of a new pharmacy benefit product addressing a currently unmet market need. RESULTS: Premera's new formulary process was developed in 2009. This presentation describes the methods used to establish incremental cost-effectiveness thresholds for each formulary tier and the constitution of an external multidisciplinary expert committee to assign specific drugs to tiers. The rationale and tier assignments for specific therapeutic drug classes are presented as examples. LESSONS LEARNED: Despite limitations to the current availability of clinical and economic outcomes from well-designed studies on which to base tiering decisions, it is possible to implement a credible process based on incremental cost-effectiveness analysis. Initial responses suggest that manufacturers will accept the challenge to improve the quality of available evidence to support future decisions. Its clinical use was limited by: high initial investment and operating costs; substantial training requirements; and lack of multicenter experience and clinical trial data from which to determine effectiveness and cost-effectiveness relative to current practices. The impact of RP on the design and work processes in the surgical theater was also unclear. Fulfilling research and education missions and enhancing prestige and profit were the primary motivators to its technological diffusion. UCA showed that patient recapture estimates of $13,000/ year would not offset the costs unique to the robotic system, and therefore, would not be economically viable. There are insufficient research data and cost benefit to justify widespread purchase and implementation of this technology solely for RP. Cautious diffusion to centers of excellence with skills and infrastructure to support the technology was recommended, as were options to help defray costs such as leasing the robotic system, providing training to outsiders and/or providing this option to the Dept of Defense. LESSONS LEARNED: The TAAG process proved feasible and effective in supporting informed and timely policy recommendations for the purchase and use of RP in a manner that enhances quality of care in a environment of cost-containment. After a one-year moratorium, VHA guidance was created to help individual facilities make an informed make or buy decision based on demonstration of an appropriate infrastructure in place to support training, backup, maintenance, and outcome data collection. The guidance included site visit and approval from the VHA National Surgery Program with oversight of outcome data collection, which continues today.
CASE3 THE VA TECHNOLOGY ASSESSMENT ADVISORY GROUP: INFORMING EVIDENCE-BASED POLICY RECOMMENDATIONS FOR ROBOTIC PROSTATECTOMY

CASE4 NEW FINDINGS FROM INTEGRATING ADMINISTRATIVE AND FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS
Wong H 1 , Levit K 2 , Sun YC 3 1 Agency for Healthcare Research and Quality, Rockville, MD, USA, 2 Thomson Reuters, Washington, DC, USA, 3 Thomson Reuters, Santa Barbara, CA, USA ORGANIZATION: Agency for Healthcare Research and Quality (funding organization), Thomson Reuters PROBLEM OR ISSUE ADDRESSED: Hospital administrative data have been used in "cost-effectiveness," "cost-benefit," and "burden-of-illness" studies because they contain large numbers of cases for specific conditions and procedures and because charge information is available. While these data generally contain information on how much the facility charged for the hospital stay, they lack information on the cost to provide care and the amount reimbursed for care. In the past, AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost of providing care. AHRQ is piloting a project to create price-to-charge ratios that will be used in conjunction with charge information collected on hospital discharge records to estimate the "price" of inpatient hospital care. The term "price" reflects the amount that hospitals are paid by insurers and consumers based on payer revenue information for each hospital. This is the amount of revenue that hospitals actually receive, net of any discounts negotiated with insurers. These ratios have been linked to the Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID) for 5 states. The HCUP SID files contain the universe of inpatient discharge abstracts (including information on charges) in participating States, translated into a uniform format to facilitate multi-State comparisons and analyses. Currently, 40 states participate in HCUP, encompassing about 90 percent of all U.S. community hospital discharges. The impetus for this project is to make health care information more transparent to consumers. While the addition of price information will help consumers make more informed choices about hospitalizations for themselves and their families, this information will also be valuable for researchers by providing alternatives to measuring resource use that are better suited for their studies. This presentation builds on last year's talk by presenting price results for 5 states. GOALS: The short-term goals of this project include: · Estimate prices by payer (Medicare, Medicaid, Private, and Self-pay) for common diagnoses in 5 states for 2006 · Assess the credibility of estimated prices ("proof-of-concept") · Evaluate price differences for major payers, geographic areas, and common diagnoses. The long term goals of this project include: · Extend study to a total of 10 states · Create models to estimate prices for HCUP states not included in the pilot · Provide states with information on hospital average prices that can be used to populate a Website where consumers can explore pricing for common diagnoses · Release prices publicly on AHRQ databases to explore inpatient pricing by market area to address research issues such as competition among hospitals, pricing differentials between payers, relationship between prices and quality, and effects of hospital entry on prices. OUTCOMES ITEMS USED IN THE DECISION: HCUP data have been used in "cost-effectiveness," "cost-benefit," and "burden-ofillness" studies because they contain large numbers of cases for specific conditions and procedures and because charge and estimated cost information is available. The addition of estimated prices will provide researchers an additional tool to more effectively conduct their studies. IMPLEMENTATION STRATEGY: AHRQ solicited participation of HCUP Partner organizations that have access to hospital revenue information by payer and are willing to release state-level charge and price information broken out by the four broad payer groups and broad diagnostic categories. Initially, AHRQ is utilizing information from 5 HCUP SID Partner States in conjunction with hospitalspecific revenue information to develop prices for hospitalizations. RESULTS: Prices have been estimated for 5 states. We show the consistency and reasonableness of estimated prices by presenting the average prices of specific diagnosis by payers, states, and metropolitan areas. In addition, average prices by bed-size, teaching status, and hospital ownership are examined. One important advantage of using "prices" rather than "costs" or "charges" is that prices are specific to each payer group, reflecting the sum of contractual and other adjustments. We demonstrate the differences in resource use as measured by "charges," "costs," and "prices." An explanation of what these concepts will be discussed. LESSONS LEARNED: To date, the lessons learned include: 1. The number of States that collect financial information by major payers for each hospital is limited. 10 States have been identified with most of the detailed information required. 2. While States may collect gross and net revenue information by payer, not all separate these revenues completely for inpatient and outpatient services and for the major payer groups. Estimating methods have been developed to address these issues. 3. Definitions of revenues and the level of detailed data collection vary considerably among States and needs to be reconciled.
PODIUM SESSION III: COMPLIANCE/ADHERENCE STUDIES
CM1 ADHERENCE, DISCONTINUATION, AND SWITCHING OF BIOLOGIC THERAPIES IN MEDICAID ENROLLEES WITH RHEUMATOID ARTHRITIS
Li P, Blum MA, Feldt JMV, Hennessy S, Doshi JA University of Pennsylvania, Philadelphia, PA, USA OBJECTIVES: Biological therapies are an expensive but important advance in the management of RA. The potential therapeutic benefits of biologics demonstrated in clinical trials may be undermined by poor adherence and early discontinuation of treatment (i.e., non-persistence) in clinical practice. This study examined adherence, discontinuation, and switching of Rheumatoid Arthritis (RA) biologics over a one year period following initiation of the biologic treatment in Medicaid patients with RA.
METHODS:
The study sample consisted of Medicaid patients with RA in California, Florida and New York who had newly initiated etanercept (n = 1359), anakinra (n = 267), or infliximab (n = 1012) between January 1, 2000 and December 31, 2002. Adherence (proportion of days covered (PDC) ≥ 0.80), discontinuation (90-day continuous gap), and switching (initiation of second biologic within 90 days of discontinuation date of index biologic) were measured during the 12-months post-index biologic initiation. Sensitivity analyses were conducted by varying the thresholds to define these measures. Logistic regressions examined the factors associated with RA biologic adherence and discontinuation. RESULTS: Anakinra users had the lowest mean PDC (0.36) and percent adherent patients (10.5%) followed by etanercept users (mean PDC:0.57; % adherent:32%) and infliximab users (mean PDC:0.64; % adherent:43%). All three groups had high discontinuation rates (41% etanercept, 76% anakinra, and 41% infliximab). Few patients who discontinued the index biologic switched to another biologic (0.2% to 9%). Logistic regressions found that patients in Florida had lower odds of being adherent and higher odds of discontinuing their index biologic than patients in California. Consistent with descriptive results, Anakinra users had lower odds and infliximab users had higher odds of being adherent than etanercept users. Anakinra users had higher odds of discontinuation than etanercept users. CONCLUSIONS: This study highlights poor adherence and premature discontinuation without concurrent switching of RA biologics that should raise concern for clinicians as well as payers.
CM2
EFFECTS OF NONADHERENCE WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS/ANGIOTENSIN RECEPTOR BLOCKERS ON HOSPITALIZATION AND MORTALITY AMONG PATIENTS WITH DIABETES
Yang Y 1 , Banahan BF 1 , Pace PF 2 1 University of Mississippi, University, MS, USA, 2 University of Mississippi, Oxford, MS, USA OBJECTIVES: The objective was to determine the effect of nonadherence to angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and subsequent diabetes-related hospitalization and mortality among patients with diabetes enrolled in a state Medicaid program. METHODS: This is a retrospective cohort study of patients with diabetes using Medicaid pharmacy and medical claims data.
